SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

Inclusion Criteria

• •Has a diagnosis of probable Alzheimer's disease based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria at least 1 year prior to the screening visit.
• •Has a score between 12 and 20 inclusive on the MMSE at the screening and baseline visits.
• •Has a MRI or CT scan performed within 12 months prior to screening with findings consistent with the diagnosis of dementia due to Alzheimer's disease without any other clinically significant comorbid pathologies.
• •Must be receiving treatment with stable doses of donepezil HCl and memantine HCl for at least 3 months prior to the screening visit
• •Availability of an eligible and reliable caregiver
• •Must be living in the community or an assisted living facility.
• •Must be ambulatory or ambulatory aided (use of cane or walker).
• •Is not pregnant or planning to become pregnant during the study.
• •Subject (or subject's legally acceptable representative) and caregiver must sign an Informed Consent to participate in the study.